DEF: MariMed Inc. Announces Notice of 2025 Annual Meeting of Stockholders

MariMed Inc. has announced its 2025 Annual Meeting of Stockholders to be held on June 12, 2025, including proposals for the election of directors and the advisory approval of independent auditors.

Summary

• MariMed Inc. will hold its 2025 Annual Meeting of Stockholders on June 12, 2025, at 9:30 a.m. Eastern Time at the Four Points by Sheraton Norwood in Massachusetts.
• Stockholders of record as of April 15, 2025, are entitled to vote at the meeting.
• The meeting will address the election of four directors, the advisory approval of M&K CPAs PLLC as the company's independent auditors for the fiscal year ending December 31, 2025, and any other business that may properly come before the meeting.
• The Board of Directors is soliciting proxies for the meeting, and stockholders are encouraged to vote via the internet, telephone, or mail.
• The company had 388,709,677 shares of common stock and 4,908,333 shares of Series B Convertible Preferred Stock outstanding as of the record date, with each share entitled to one vote.
• A quorum requires a majority of the outstanding shares to be present in person or by proxy.
• The election of directors requires a plurality of votes cast, while the approval of auditors requires a majority of votes cast.
• Kathleen Tucker will not stand for reelection at the Annual Meeting.
• Ryan Crandall was appointed Chief Commercial Officer in April 2025.
• In January 2025, Mr. Levine voluntarily agreed to reduce his annual base salary to $300,000 for 2025.
• The company's corporate offices are leased from an entity in which the CEO has an investment interest, with expenses of approximately $233,000 in 2024.
• The company procures nutrients, lab equipment, cultivation supplies, furniture, and tools from an entity owned by the family of the COO, with purchases totaling $4.6 million in 2024.
• The company pays royalties on the revenue generated from its Bettys Eddies product line to an entity owned by the COO and the Company's Chief Commercial Officer under a royalty agreement, with aggregate royalties of approximately $634,000 in 2024.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The information is presented in a factual manner, with no explicit positive or negative sentiment expressed. The presence of related party transactions and a director involved in a bankruptcy matter slightly lowers the score.

Positives

• The Board is actively seeking stockholder input through the proxy voting process.
• The Audit Committee is comprised entirely of independent directors.
• The company has a Code of Ethics in place for its Board, executive officers, and employees.
• The Board has a process to receive communications from stockholders.
• The Audit Committee pre-approves all audit and non-audit services performed by the independent registered public auditors.

Negatives

• David Allen, a director, is a named defendant in the Iconic Bankruptcy Matter.
• The company's corporate offices are leased from an entity in which the CEO has an investment interest.
• The company procures nutrients, lab equipment, cultivation supplies, furniture, and tools from an entity owned by the family of the COO.
• The company pays royalties on the revenue generated from its Bettys Eddies product line to an entity owned by the COO and the Company's Chief Commercial Officer under a royalty agreement.

Risks

• The document mentions a bankruptcy proceeding involving a company where David Allen, a director, served as CFO, which could raise concerns about his financial oversight capabilities.
• Related party transactions, such as leasing office space from an entity with the CEO's investment interest and procuring supplies from an entity owned by the COO's family, could present potential conflicts of interest.
• The reliance on personal guarantees from the CEO for company mortgages could pose a risk if the company faces financial difficulties.

Future Outlook

The document outlines the procedures and deadlines for stockholders to submit proposals and director nominations for the next annual meeting, indicating a focus on corporate governance and stockholder engagement.

Management Comments

• Edward Gildea, Chairman of the Board: 'Thank you for your continued support, interest and investment in MariMed.'

Industry Context

In the context of the cannabis industry, this proxy statement reflects standard corporate governance practices, including the election of directors, appointment of auditors, and disclosure of executive compensation and related party transactions. The company's focus on stockholder engagement and compliance with SEC regulations aligns with the increasing maturity and regulatory scrutiny of the cannabis market.

Comparison to Industry Standards

• The director compensation structure, including annual retainers and equity grants, is comparable to other publicly traded cannabis companies.
• The related party transactions disclosed are not uncommon in the cannabis industry, where companies often have close relationships with founders and early investors.
• The company's commitment to independent board committees and a code of ethics aligns with best practices in corporate governance.

Management Changes

Corporate Governance

Legal Proceedings

• David Allen, a director, is a named defendant in the Iconic Bankruptcy Matter.

Related Party Transactions

• The company's corporate offices are leased from an entity in which the CEO has an investment interest.
• The company procures nutrients, lab equipment, cultivation supplies, furniture, and tools from an entity owned by the family of the COO.
• The company pays royalties on the revenue generated from its Bettys Eddies product line to an entity owned by the COO and the Company's Chief Commercial Officer under a royalty agreement.
• One of the Company's majority-owned subsidiaries paid distributions to the CEO, who owns a minority equity interest in such subsidiary.
• First State Compassion Center (FSCC) paid fees to BKR Management Inc., a company partially owned by the CEO, related to the initial formation, licensing and establishment of FSCC's cannabis operations.
• The Company had an outstanding accounts payable balance in connection with fixed assets purchased from a third-party company in which the CEO has a controlling interest.
• The CEO and COO purchased membership units of Mari Holdings Metropolis LLC, one of the Company's majority-owned subsidiaries.
• The Company's mortgages with Bank of New England and DuQuoin State Bank were personally guaranteed by the CEO.

Stakeholder Impact

• Stockholders are asked to vote on key proposals, including the election of directors and the appointment of auditors.
• Executive compensation and related party transactions are disclosed, providing transparency to stakeholders.
• The company's corporate governance practices are outlined, which can impact investor confidence.
• The personal guarantees provided by the CEO could impact the company's financial stability and its relationship with lenders.

Next Steps

• Stockholders are encouraged to review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 12, 2025.
• The Board will consider the outcome of the advisory vote on the appointment of independent auditors.
• The company will prepare for the 2026 Annual Meeting, including soliciting proposals and director nominations from stockholders.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Director Election, Independent Auditors, Executive Compensation, Related Party Transactions, Corporate Governance, MariMed Inc., Stockholders